pf 2341066

Crizotinib, an orally bioavailable agent, belongs to the class of c-met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors with potential antineoplastic activity.

Crizotinib-[13C2,D5] (Standard) is a reference standard of Crizotinib-[13C2,D5] intended for quantitative analysis, quality control, and related biochemical research applications.

Crizotinib-D5 is a deuterated compound of Crizotinib. Crizotinib (T1661) has a CAS number of 877399-52-5. Crizotinib (T1661) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.

Crizotinib-D5 (Standard) is a reference standard of Crizotinib-D5 intended for quantitative analysis, quality control, and related biochemical research applications. Crizotinib-d5 is a deuterated compound of Crizotinib. Crizotinib has a CAS number of 877399-52-5. Crizotinib is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.

Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinase inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptors.

Crizotinib (Standard) is a reference standard for research and analysis in studies involving Crizotinib. Crizotinib (PF-02341066) is a small molecule tyrosine kinase inhibitor that inhibits c-MET and ALK receptors (IC50=8/20 nM), is ATP-competitive, and also inhibits ROS1. Crizotinib exhibits antitumor activity and inhibits tumor growth.

(S)-crizotinib (ent-crizotinib) （IC50 of 72 nM）, an effective MTH1 (NUDT1) inhibitor, is the (S)-enantiomer of crizotinib.

Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met, with IC50 values of 20 nM and 8 nM, respectively.